Clinical Trials Logo

Septic Shock clinical trials

View clinical trials related to Septic Shock.

Filter by:

NCT ID: NCT02990546 Withdrawn - Septic Shock Clinical Trials

Midodrine in the Recovery Phase of Septic Shock

Start date: March 1, 2017
Phase: Phase 3
Study type: Interventional

The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.

NCT ID: NCT02885688 Withdrawn - Septic Shock Clinical Trials

Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if adding liquid nutrition therapy that is given by vein to standard-of-care treatment for sepsis can help to control sepsis symptoms better than giving standard-of-care treatment alone. Researchers also want to compare the length of ICU and hospital stay and any side effects between these 2 treatments.

NCT ID: NCT02699905 Withdrawn - Sepsis Clinical Trials

Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis

GPR43Sepsis
Start date: August 2016
Phase: N/A
Study type: Observational

This study seeks to elucidate the quantitative expression of G - protein receptor 43/free fatty acid (GPR43/FFA2) receptors in patients with the diagnosis of sepsis and specifically, its expression as it relates to the severity of sepsis. The investigators hypothesize that patients with more severe sepsis, as defined by a higher SOFA (Sequential Organ Failure Assessment Score), will have decreased expression of the GPR43/FFA2 as compared to patients with lower SOFA scores, consistent with a less exuberant immune response to infection. Patients admitted to Penn State Hershey Medical Center with a diagnosis of sepsis of any cause will undergo blood testing of leukocytes to determine the expressed quantity of GP43 during standardized time points of their illness and recovery. No interventions will be made in the standard clinical management of the patient. Additionally, healthy volunteers will be recruited to exam baseline GPR43 receptor expression between sepsis and control groups.

NCT ID: NCT02069288 Withdrawn - Septic Shock Clinical Trials

Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock

FLUDRO
Start date: n/a
Phase: Phase 3
Study type: Interventional

Septic shock (associated with relative adrenal insufficiency) is characterized by decreased arterial responsiveness to catecholamines. The association of hydrocortisone and fludrocortisone has demonstrated an improvement in survival in septic shock patients. If hydrocortisone has shown to increase vascular responsiveness, the role of fludrocortisone remains to be elucidated. The purpose of our study is to investigate the effect of a physiological dose of fludrocortisone alone on norepinephrine-mean arterial pressure dose-response relationship, gastric mucosal perfusion and arterial stiffness in patients with septic shock.

NCT ID: NCT01926301 Withdrawn - Septic Shock Clinical Trials

Cerebrovascular Autoregulation in Sepsis, Influence of Renal Replacement Therapy

SepsAR2
Start date: August 2013
Phase:
Study type: Observational

The cerebrovascular autoregulation is impaired in patients with severe sepsis and septic shock. A continuous veno-venous hemodialysis may improve impaired cerebrovascular autoregulation. Hypothesis: continuous hemodialysis recovers impaired cerebrovascular autoregulation in patients with acute severe sepsis and septic shock.

NCT ID: NCT01573806 Withdrawn - Inflammation Clinical Trials

Pharmacology of Exenatide in Pediatric Sepsis

PEPS
Start date: October 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Pharmacology of Exenatide in Pediatric Sepsis, PEPS is a phase 1-2 research study that will examine drug safety, drug metabolism, drug action and preliminary drug clinical effects of four does of exenatide injected every 12 hours to children with shock from infection (septic shock). The investigators hypothesize that exenatide can be safely dosed to children with sepsis to achieve blood levels of drug similar to that achieved in teenagers with type 2 diabetes. The investigators further hypothesize that injection of exenatide to children with septic shock will normalize blood glucose levels and decrease levels of inflammation proteins in the blood during the early course of sepsis.

NCT ID: NCT01063010 Withdrawn - Septic Shock Clinical Trials

Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

Start date: February 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to perform a pilot study to assess the potential use of Bevacizumab (a vascular endothelial growth factor (VEGF) inhibitor) in sepsis.

NCT ID: NCT00814112 Withdrawn - Septic Shock Clinical Trials

Glycosaminoglycans During Septic Shock - a Temporal Study

GAGS
Start date: November 2008
Phase:
Study type: Observational

We have previously shown that the plasma level of glycosaminoglycans (GAG) in septic shock patients are elevated compared to controls. The purpose of this study is to investigate the temporal dynamic of the blood level of GAG in ten septic shock patients. In addition, to assess the kinetics of GAG during septic shock we examine the liver function by galactose elimination capacity as well as excreted urinary GAG.